# MannKind Corporation (MNKD) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $4.06, market value $1.3 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). MannKind Corporation reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 3.3×**. Each dollar of revenue is priced at 3.3×.
- **EV / EBITDA: 52.7×**. Enterprise value is 52.7× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: -1.4%** (5-yr avg -2.3%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: 2.3%**. 2.3% of revenue is left after running the business, which leaves little cushion in a downturn.
- **Net margin: 1.7%**. 1.7% of each dollar of sales reaches the bottom line.
- **Return on equity: -11.5%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 3.2%**. Return on all capital, debt included, is 3.2%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -5.5%**. Each dollar of assets produces -5.5% of profit.

## Growth
- **Revenue growth (1 yr): 22.2%** (3-yr 51.8%/yr, 5-yr 39.9%/yr). Revenue grew 22.2% over the last year, against 39.9% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -80.0%**. Earnings per share fell 80.0%, slower than revenue, so margins compressed.

## Financial health
- **Net debt / EBITDA: 9.3×**. It would take 9.3 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Altman Z-score: 1.44**. A Z-score of 1.44 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. MannKind Corporation does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): -24.0%** (YTD -28.4%, 3-mo 19.4%). The shares are down 24.0% over twelve months including dividends.
- **From 52-week high: -37.6%** (82.1% above the low). Trading 38% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 52**. An RSI of 52 is neutral.
- **Beta (1 yr): 0.99** (volatility 68%). Beta of 0.99 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=MNKD · Page: https://foliofundamentals.com/stocks/mnkd

Not investment advice.